You just read:

PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)

News provided by

PARI Pharma

03 Oct, 2018, 13:00 BST